FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281683246> ?p ?o ?g. }

• W4281683246 endingPage "742" @default.
• W4281683246 startingPage "734" @default.
• W4281683246 abstract "Antigen-directed target therapy for B-cell acute lymphoblastic leukemia (B-ALL) is now the standard of care for relapsed/refractory (R/R) disease. A comprehensive determination of the target itself is mandatory to aid physician's choice. We determined baseline Cluster of differentiation 22 (CD22) expression percentage and fluorescent intensity on lymphoblasts of 30 patients with R/R B-ALL treated with anti-CD22 immunoconjugate drug Inotuzumab Ozogamicin (INO) and analyzed the impact of both parameters on patient outcome. Most patients (24/30, 80%) had a high leukemic blast CD22-positivity defined as ≥90%. We did not observe a benefit in terms of complete remission, overall survival (OS) and duration of response (DoR) for patients with CD22 ≥ 90% versus CD22 < 90%. Concerning CD22-FI quartile analysis we appreciated a trend for superior response rates in higher quartiles (Q2 -Q4 ) compared to Q1 and a significant benefit in terms of OS and DoR for patients with higher CD22-FI. INO demonstrates to be effective also in patients with lower CD22 expression, but therapeutical benefits are more evident in patients with higher CD22-FI. The evaluation of both CD22 percentage and CD22-FI of the leukemic blast may help physicians in therapeutic choices for R/R B-ALL patients when multiple treatment options are available, although no CD22 expression threshold can currently be identified below which INO should be considered not effective." @default.
• W4281683246 created "2022-06-13" @default.
• W4281683246 creator A5000893813 @default.
• W4281683246 creator A5014370854 @default.
• W4281683246 creator A5015623905 @default.
• W4281683246 creator A5019480794 @default.
• W4281683246 creator A5025719686 @default.
• W4281683246 creator A5031314858 @default.
• W4281683246 creator A5036642940 @default.
• W4281683246 creator A5042328462 @default.
• W4281683246 creator A5044624520 @default.
• W4281683246 creator A5047468243 @default.
• W4281683246 creator A5063427645 @default.
• W4281683246 creator A5071926851 @default.
• W4281683246 creator A5072253025 @default.
• W4281683246 creator A5072605763 @default.
• W4281683246 creator A5074486528 @default.
• W4281683246 creator A5085520305 @default.
• W4281683246 creator A5086339138 @default.
• W4281683246 date "2022-06-05" @default.
• W4281683246 modified "2023-09-26" @default.
• W4281683246 title "Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment" @default.
• W4281683246 cites W1943300686 @default.
• W4281683246 cites W1970384544 @default.
• W4281683246 cites W1990480706 @default.
• W4281683246 cites W2038750132 @default.
• W4281683246 cites W2039642633 @default.
• W4281683246 cites W2066508515 @default.
• W4281683246 cites W2119147717 @default.
• W4281683246 cites W2141019574 @default.
• W4281683246 cites W2159507916 @default.
• W4281683246 cites W2419639370 @default.
• W4281683246 cites W2516611622 @default.
• W4281683246 cites W2591709377 @default.
• W4281683246 cites W2614019261 @default.
• W4281683246 cites W2725925241 @default.
• W4281683246 cites W2725970815 @default.
• W4281683246 cites W2787621143 @default.
• W4281683246 cites W2893525181 @default.
• W4281683246 cites W2931981435 @default.
• W4281683246 cites W3003422194 @default.
• W4281683246 cites W3103532691 @default.
• W4281683246 cites W3106146043 @default.
• W4281683246 cites W3108928978 @default.
• W4281683246 cites W3113577374 @default.
• W4281683246 cites W4376595466 @default.
• W4281683246 doi "https://doi.org/10.1002/hon.3029" @default.
• W4281683246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35618655" @default.
• W4281683246 hasPublicationYear "2022" @default.
• W4281683246 type Work @default.
• W4281683246 citedByCount "2" @default.
• W4281683246 countsByYear W42816832462023 @default.
• W4281683246 crossrefType "journal-article" @default.
• W4281683246 hasAuthorship W4281683246A5000893813 @default.
• W4281683246 hasAuthorship W4281683246A5014370854 @default.
• W4281683246 hasAuthorship W4281683246A5015623905 @default.
• W4281683246 hasAuthorship W4281683246A5019480794 @default.
• W4281683246 hasAuthorship W4281683246A5025719686 @default.
• W4281683246 hasAuthorship W4281683246A5031314858 @default.
• W4281683246 hasAuthorship W4281683246A5036642940 @default.
• W4281683246 hasAuthorship W4281683246A5042328462 @default.
• W4281683246 hasAuthorship W4281683246A5044624520 @default.
• W4281683246 hasAuthorship W4281683246A5047468243 @default.
• W4281683246 hasAuthorship W4281683246A5063427645 @default.
• W4281683246 hasAuthorship W4281683246A5071926851 @default.
• W4281683246 hasAuthorship W4281683246A5072253025 @default.
• W4281683246 hasAuthorship W4281683246A5072605763 @default.
• W4281683246 hasAuthorship W4281683246A5074486528 @default.
• W4281683246 hasAuthorship W4281683246A5085520305 @default.
• W4281683246 hasAuthorship W4281683246A5086339138 @default.
• W4281683246 hasConcept C111700020 @default.
• W4281683246 hasConcept C126322002 @default.
• W4281683246 hasConcept C142424586 @default.
• W4281683246 hasConcept C143998085 @default.
• W4281683246 hasConcept C18031839 @default.
• W4281683246 hasConcept C204232928 @default.
• W4281683246 hasConcept C44249647 @default.
• W4281683246 hasConcept C68443243 @default.
• W4281683246 hasConcept C71924100 @default.
• W4281683246 hasConcept C86803240 @default.
• W4281683246 hasConcept C87355193 @default.
• W4281683246 hasConceptScore W4281683246C111700020 @default.
• W4281683246 hasConceptScore W4281683246C126322002 @default.
• W4281683246 hasConceptScore W4281683246C142424586 @default.
• W4281683246 hasConceptScore W4281683246C143998085 @default.
• W4281683246 hasConceptScore W4281683246C18031839 @default.
• W4281683246 hasConceptScore W4281683246C204232928 @default.
• W4281683246 hasConceptScore W4281683246C44249647 @default.
• W4281683246 hasConceptScore W4281683246C68443243 @default.
• W4281683246 hasConceptScore W4281683246C71924100 @default.
• W4281683246 hasConceptScore W4281683246C86803240 @default.
• W4281683246 hasConceptScore W4281683246C87355193 @default.
• W4281683246 hasIssue "4" @default.
• W4281683246 hasLocation W42816832461 @default.
• W4281683246 hasLocation W42816832462 @default.
• W4281683246 hasOpenAccess W4281683246 @default.
• W4281683246 hasPrimaryLocation W42816832461 @default.
• W4281683246 hasRelatedWork W2068316626 @default.

• next